← All trials

NCT04856982

Phase 3Interventional

Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.

View on ClinicalTrials.gov ↗

Timeline

Start date
May 17, 2021
Primary completion
Aug 7, 2026
Completion date
Aug 7, 2027
First posted
Apr 23, 2021
Last posted
Nov 8, 2021
Enrollment
150
Arms / groups
4 / —
Source
AACT · ingestion pipeline

Sponsors

Drugs studied

Indications studied

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.